XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
Revenues $ 5,009,436 $ 3,524,331
Cost of goods sold 474,433 330,188
Gross profit 4,535,003 3,194,143
Operating expenses    
Selling, general and administrative expense 5,409,730 4,932,151
Research and development 118,212 4,387
Depreciation and amortization 90,591 53,505
Total operating expenses 5,618,533 4,990,043
Operating loss (1,083,530) (1,795,900)
Other income / (expense)    
Other expense 0 (36,758)
Interest expense (711) (8,354)
Share of losses from equity method investment (99,135) 0
Total other expense (99,846) (45,112)
Net loss (1,183,376) (1,841,012)
Less: net loss attributable to noncontrolling interest (1,632) (4,055)
Net loss attributable to Sanara MedTech common shareholders $ (1,181,744) $ (1,836,957)
Net loss per share of common stock, basic and diluted $ (0.17) $ (0.39)
Weighted average number of common shares outstanding, basic and diluted 6,816,646 4,751,941